SEC Form 4 · accession 0001179110-16-029709
INVIVO THERAPEUTICS HOLDINGS CORP. · NVIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pamela J Stahl
Officer — Chief Commercial Officer
Period of report
Sep 14, 2016
Accepted (ET)
Sep 16, 2016 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001292519
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.47 | Sep 14, 2016 | A | 188,200 | A | — | Sep 14, 2026 | Common Stock | 188,200 | 188,200 | D |
Explanation of responses
- F1This option vests as to 25% of the shares on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal monthly installments thereafter.